Item 8.01 Other Events
On
Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those that express plans, anticipation,
intent, contingencies, goals, targets or future development and/or otherwise are
not statements of historical fact. These statements relate to future events or
future results of operations, including, but not limited to the following
statements: the company's beliefs concerning the safety and effectiveness of
Tempol; the timing of funding for, or commencement or completion of, any studies
or trials relating to Tempol; the availability of, and the company's success in
applying for and obtaining, government or other funding for studies or trials
relating to Tempol or the timing or amount of any such funding; the results of
any future studies or trials that the company may conduct relating to Tempol;
the company's ability to commercialize the product candidates described in this
Report, itself or through commercialization partners; and other statements
concerning our future operations and activities. These statements are only
predictions and involve known and unknown risks, uncertainties and other
factors, which may cause Adamis' actual results to be materially different from
the results anticipated by such forward-looking statements. There are no
assurances whether final data produced from the study discussed in the press
release attached as an exhibit to this Report will be consistent with the
preliminary data or the extent to which Tempol will be shown to decrease
cytokines from stimulated cells from COVID-19 patients. There can be no
assurances regarding the outcome of trials or studies relating to Tempol;
regarding the timing or the outcome of any applications or requests that we may
submit for government or other funding for studies or trials relating to Tempol;
concerning the timing or outcome of any such studies or trials; or that Tempol
will be found to be safe and effective in the treatment of COVID-19 or any other
indication. In addition, forward-looking statements concerning our anticipated
future activities assume that we are able to obtain sufficient funding to
support such activities and continue our operations and planned activities. As
discussed in our filings with the
Item 9.01
© Edgar Online, source